Biogen to Acquire RayThera for Up to $1 Billion, Bolstering Immunology Pipeline
BIIB sits 65% above its 52-week low of $121.05.
Summary
Biogen announced an agreement to acquire private biotechnology company RayThera for up to $1 billion. This strategic move aims to expand Biogen's pipeline in immunology. This follows the company's recent completion of the $5.3 billion Apellis Pharmaceuticals acquisition in May, indicating continued focus on M&A for pipeline growth. The $1 billion investment is a material commitment to its immunology franchise.
At the time of this announcement, BIIB was trading at $199.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.3B. The 52-week trading range was $121.05 to $205.97. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.